Arcus Biosciences Appoints William Grossman, M.D., Ph.D., Chief Medical Officer

HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical
company focused on creating innovative cancer immunotherapies, today
announced that William Grossman, M.D., Ph.D. has joined the Company as
Chief Medical Officer. Dr. Grossman will oversee all aspects of the
Company’s global clinical development strategy and operations.

“We are pleased to have Dr. Grossman join Arcus during this seminal
period in the advancement and expansion of our clinical development
programs,” said Terry Rosen, Ph.D., Chief Executive Officer of Arcus.
“Dr. Grossman has a distinguished background as a practicing oncologist
and has successfully led multiple global cancer immunotherapy trials,
from early-stage to commercialization. He will complement the
outstanding team that has already been assembled and advanced Arcus’s
first four product candidates into clinical development. I look forward
to having Bill as a colleague and critical member of our senior
leadership team as we move towards later stage clinical trials.”

“I am honored to join Arcus at this pivotal time, with multiple Phase 1
readouts in 2019,” commented Dr. Grossman. “Arcus’s thoughtful strategy
in leveraging promising biological targets, potentially best-in-class
molecules, comprehensive and unique approach to clinical development and
experienced team were key reasons for joining the Company. I look
forward to contributing to the shared commitment of developing
innovative cancer immunotherapies for patients.”

Dr. Grossman has extensive experience leading successful global clinical
organizations, including direct medical accountability for more than 50
clinical trials spanning Phase 1 through Phase 3. Dr. Grossman joins
Arcus from Bellicum Pharmaceuticals, where he served as Chief Medical
Officer and was responsible for the company’s clinical development,
regulatory affairs, clinical operations, and medical affairs
organizations. Prior to Bellicum, Dr. Grossman was the Global Group
Medical Director for Cancer Immunotherapy at Genentech, where he led the
clinical development of TECENTRIQ® in gastrointestinal cancers and of
cancer immunotherapy combinations across all solid tumor types. Dr.
Grossman designed and led the Phase 1b/2 MORPHEUS platform, a rapid and
efficient paradigm for the evaluation of cancer immunotherapy
combinations. Before joining Genentech, Dr. Grossman led the development
and execution of the U.S. & Global medical affairs strategy for the
oncology franchise at AbbVie. Previously, he served as Senior Vice
President, Research & Clinical Development at Biothera, where he oversaw
all discovery and clinical development efforts in oncology and
immunology. In addition, Dr. Grossman has held leadership positions in
research, clinical development, and medical affairs at Baxter Healthcare
and Merck & Co., where he was involved in the clinical evaluation of
anti-cancer vaccines, immunomodulatory agents, small molecules and
biologics for oncology.

Prior to joining the industry, Dr. Grossman held various positions with
the Children’s Hospital of Wisconsin/Medical College of Wisconsin where
he was Founder and Medical Director of the Clinical Immunodiagnostic and
Research Laboratory, Professor for Microbiology and Genetics, and
Director of the Hematology/Oncology/Bone Marrow Transplant Division for
the Immunodeficiency Transplant Program. Dr. Grossman earned his M.D.
and Ph.D. (Immunology) degrees from Washington University School of
Medicine’s Medical Scientist Training Program and completed his medical
training in the Division of Pediatric Biology/Medicine at the Washington
University School of Medicine.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused
on creating innovative cancer immunotherapies. Arcus has several
programs targeting important immuno-oncology pathways, including a dual
adenosine receptor antagonist, AB928, which is in a Phase 1/1b program
to evaluate AB928 in combination with other agents in multiple tumor
types, and an anti-PD-1 antibody, AB122, which is being evaluated in a
Phase 1 trial and is being tested in combination with Arcus’s other
product candidates. Arcus’s other programs include AB154, an anti-TIGIT
antibody, which is being evaluated in a Phase 1 trial as monotherapy and
in combination with AB122, and AB680, a small-molecule inhibitor of
CD73, which is in a Phase 1 healthy volunteer study. Arcus has extensive
in-house expertise in medicinal chemistry, immunology, biochemistry,
pharmacology and structural biology. For more information about Arcus
Biosciences, please visit www.arcusbio.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements
other than statements of historical facts contained herein, including,
but not limited to, Arcus’s strategy and expectations regarding the
advancement and potential of its clinical development programs, are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements involve known and unknown risks,
uncertainties and other important factors that may cause Arcus’s actual
results, performance or achievements to differ significantly from those
expressed or implied. Factors that could cause or contribute to such
differences include, but are not limited to, the inherent uncertainty
associated with pharmaceutical product development and clinical trials,
the emergence of adverse events or other undesirable side effects,
delays in our clinical trials due to difficulties or delays in the
regulatory process, enrolling subjects or manufacturing or supplying
product for such clinical trials, and changes in the competitive
landscape for our programs. Risks and uncertainties facing Arcus are
described more fully in Arcus’s most recent Annual Report on Form 10-K
and Quarterly Report on Form 10-Q filed with the U.S. Securities and
Exchange Commission. You are cautioned not to place undue reliance on
the forward-looking statements, which speak only as of the date of this
press release. Arcus disclaims any obligation or undertaking to update,
supplement or revise any forward-looking statements contained in this
press release.

TECENTRIQ® is a registered trademark of Genentech, Inc.

Source: Arcus Biosciences

Contacts

Katherine Bock
(415) 533-5670
[email protected]

Nicole Arndt
(510) 284-4728
[email protected]